Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0516 CHF | -13.71% | -18.10% | +25.85% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
Sales 2021 | 331 364.04 | Sales 2022 | 1.48M 1.62M | Capitalization | 19.96M 21.95M |
---|---|---|---|---|---|
Net income 2021 | -11M -12.1M | Net income 2022 | -18M -19.8M | EV / Sales 2021 * | - |
Net cash position 2021 | 6.23M 6.86M | Net Debt 2022 | 4.23M 4.66M | EV / Sales 2022 | 16.4 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.07
x | Employees | 28 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 46.61% |
Latest transcript on Spexis AG
1 day | -13.71% | ||
1 week | -18.10% | ||
Current month | -39.29% | ||
1 month | -42.67% | ||
3 months | -72.11% | ||
6 months | -72.98% | ||
Current year | +25.85% |
Managers | Title | Age | Since |
---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 21-12-29 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 21-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 21-12-29 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 21-12-29 |
Kuno Sommer
BRD | Director/Board Member | 68 | 12-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.0516 | -13.71% | 117,601 |
24-04-17 | 0.0598 | +8.73% | 237,392 |
24-04-16 | 0.055 | -13.79% | 111,043 |
24-04-15 | 0.0638 | -1.85% | 700 |
24-04-12 | 0.065 | +3.17% | 541,906 |
Delayed Quote Swiss Exchange, April 18, 2024 at 11:30 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.85% | 3.83M | |
-5.99% | 84.46B | |
+3.95% | 40.85B | |
-26.37% | 27.69B | |
+50.89% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-2.85% | 8.07B |
- Stock Market
- Equities
- POLN Stock